A randomized, crossover trial comparing the efficacy and safety of fesoterodine and extended-release...
A randomized, crossover trial comparing the efficacy and safety of fesoterodine and extended-release oxybutynin in children with overactive bladder with 12-month extension on fesoterodine: The FOXY study
About this item
Full title
Author / Creator
Publisher
Canada: Canadian Urological Association
Journal title
Language
English
Formats
Publication information
Publisher
Canada: Canadian Urological Association
Subjects
More information
Scope and Contents
Contents
We sought to assess and compare safety and efficacy of fesoterodine and oxybutynin extended-release in the treatment of pediatric overactive bladder (OAB).
We conducted a non-inferiority, randomized, double-blind, crossover trial comparing fesoterodine 4-8 mg and oxybutynin 10-20 mg QD in children with OAB aged 5-14 years (2015-2018). Every chil...
Alternative Titles
Full title
A randomized, crossover trial comparing the efficacy and safety of fesoterodine and extended-release oxybutynin in children with overactive bladder with 12-month extension on fesoterodine: The FOXY study
Authors, Artists and Contributors
Author / Creator
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7654663
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7654663
Other Identifiers
ISSN
1911-6470
E-ISSN
1920-1214
DOI
10.5489/cuaj.6247
